lanthanum carbonate has been researched along with Cardiovascular Diseases in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 12 (60.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akizawa, T; Fukagawa, M; Fukushima, M; Hirakata, H; Kagimura, T; Ogata, H | 1 |
| Li, H; Lu, X; Wang, F; Wang, S; Xiong, R; Zhang, J | 1 |
| Badve, SV; Elder, G; Hawley, C; Lioufas, N; Pascoe, E; Pedagogos, E; Toussaint, ND; Valks, A | 1 |
| Bierhals, AJ; Cheng, SC; Dávila-Román, VG; de las Fuentes, L; Dietzen, DJ; Hruska, KA; Ross, W; Rothstein, M; Seifert, ME; Windus, D | 1 |
| Chen, H; Liu, L; Wang, Y; Yang, Y; Zhou, L; Zhu, X | 1 |
| Hanafusa, N | 1 |
| Kawashima, S; Minakuchi, J; Nagai, K; Tsuchida, K; Yokota, N | 1 |
| Akizawa, T; Fukagawa, M; Hirakata, H; Kagimura, T; Kaneda, H; Ogata, H | 1 |
| Anderson, CA; Nguyen, HA; Rifkin, DE | 1 |
| Valdivieso, JM | 1 |
| Fernandez Giraldez, E; Sánchez González, MC; Valdivielso Revilla, JM | 1 |
| Spasovski, G | 1 |
| Hutchison, AJ; Mohammed, I | 1 |
| Orita, H; Shigematsu, T; Tanaka, Y; Yamanaka, S; Yoshimoto, W | 1 |
| Negi, S; Shigematsu, T | 1 |
| Fujii, H; Fujimori, A; Fukagawa, M; Goto, S; Hasegawa, H; Kamae, I; Kim, JI; Komaba, H; Moriwaki, K; Nishi, S; Nishioka, M; Shibuya, K; Shin, J; Taniguchi, M; Yoshiya, K | 1 |
| Akehurst, R; Goldsmith, D; Hodgkins, P; Keith, MS; Park, H; Rascati, KL; Smyth, M | 1 |
| Albaaj, F; Hutchison, A | 1 |
| Bellinghieri, G; Calò, LA; Monardo, P; Santoro, D; Savica, V | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
13 review(s) available for lanthanum carbonate and Cardiovascular Diseases
| Article | Year |
|---|---|
Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
Topics: Calcium; Cardiovascular Diseases; Humans; Hyperphosphatemia; Lanthanum; Mortality; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2018 |
The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.
Topics: Biomarkers; Bone Remodeling; Calcium; Calcium Phosphates; Cardiovascular Diseases; Chelating Agents; Humans; Lanthanum; Polyamines; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer; Vascular Calcification | 2014 |
[Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Topics: Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Drug Discovery; Humans; Hyperphosphatemia; Japan; Lanthanum; Polyamines; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2015 |
Nutrition Interventions in Chronic Kidney Disease.
Topics: Body Weight; Calcium Carbonate; Cardiovascular Diseases; Chelating Agents; Diet; Diet, Mediterranean; Dyslipidemias; Exercise; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperglycemia; Lanthanum; Phosphorus, Dietary; Protein-Energy Malnutrition; Renal Insufficiency, Chronic; Sodium, Dietary; Water-Electrolyte Balance | 2016 |
[Experimental advances in mineral metabolism].
Topics: Animals; Calcinosis; Calcium; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Chronic Disease; Drug Evaluation, Preclinical; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Intestinal Absorption; Kidney; Kidney Diseases; Lanthanum; Phosphorus; Sodium-Phosphate Cotransporter Proteins | 2008 |
[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
Topics: Calcifediol; Calcinosis; Calcitriol; Cardiovascular Diseases; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphorus; Polyamines; Prevalence; Renal Dialysis; Sevelamer; Vitamin D; Vitamin D Deficiency | 2008 |
New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease.
Topics: Calcinosis; Cardiovascular Diseases; Chronic Disease; Humans; Kidney Diseases; Lanthanum; Minerals; Parathyroid Hormone; Phosphates; Polyamines; Sevelamer | 2008 |
Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Topics: Acetates; Administration, Oral; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Chelating Agents; Drug Monitoring; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Magnesium; Nephrology; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Chronic Disease; Contraindications; Dialysis; Diphosphonates; Fractures, Spontaneous; Kidney Diseases; Lanthanum; Minerals; Polyamines; Sevelamer | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Topics: Cardiovascular Diseases; Chronic Disease; Drug Design; Hyperphosphatemia; Kidney Diseases; Lanthanum; Renal Dialysis; Risk | 2010 |
Hyperphosphataemia in renal failure: causes, consequences and current management.
Topics: Aluminum; Calcinosis; Calcitriol; Calcium; Cardiovascular Diseases; Chlorides; Epoxy Compounds; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Lanthanum; Magnesium; Phosphates; Polyamines; Polyethylenes; Renal Dialysis; Sevelamer; Uronic Acids; Zirconium | 2003 |
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Topics: Acetates; Aluminum Compounds; Bone Diseases, Metabolic; Calcinosis; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Central Nervous System Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Diet, Protein-Restricted; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Sevelamer | 2006 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
5 trial(s) available for lanthanum carbonate and Cardiovascular Diseases
| Article | Year |
|---|---|
Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Topics: Aged; Calcium Carbonate; Cardiovascular Diseases; Female; Heart Disease Risk Factors; Hip Fractures; Humans; Hyperparathyroidism; Hyperphosphatemia; Incidence; Japan; Lanthanum; Male; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Survival Analysis; Vascular Calcification | 2021 |
Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Topics: Adult; Cardiovascular Diseases; Clinical Protocols; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Male; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic | 2019 |
Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Feasibility Studies; Female; Homeostasis; Humans; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Phosphorus, Dietary; Pilot Projects; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome; Vascular Stiffness | 2013 |
Design and baseline characteristics of the LANDMARK study.
Topics: Aged; Biomarkers; Calcium Carbonate; Cardiovascular Diseases; Chelating Agents; Clinical Protocols; Disease-Free Survival; Female; Humans; Hyperphosphatemia; Japan; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Research Design; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Biomarkers; Cardiovascular Diseases; Chelating Agents; Cost-Benefit Analysis; Drug Costs; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Models, Economic; Phosphorus; Quality-Adjusted Life Years; Renal Dialysis; Time Factors; Treatment Outcome; Young Adult | 2011 |
2 other study(ies) available for lanthanum carbonate and Cardiovascular Diseases
| Article | Year |
|---|---|
Impact of Lanthanum Carbonate on Prognosis of Chronic Hemodialysis Patients: A Retrospective Cohort Study (Kawashima Study).
Topics: Aged; Cardiovascular Diseases; Chelating Agents; Cohort Studies; Disease Progression; Female; Humans; Lanthanum; Male; Middle Aged; Phosphorus; Prognosis; Proportional Hazards Models; Renal Dialysis; Retrospective Studies; Treatment Outcome; Vascular Calcification | 2016 |
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
Topics: Cardiovascular Diseases; Chelating Agents; Cost-Benefit Analysis; Cross-Over Studies; Databases, Factual; Economics, Pharmaceutical; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Polyamines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Sevelamer; United States | 2011 |